image

The best stocks to buy since 1993

Latest issue now available

EMIS - 220 now working towards a new version of clinical management system EMIS-X

April 2019

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • EMIS
  • Price:
  • 1056p
EMIS’ shares have returned to form. Full year results show sales growing once more, up 6% to £170.1m, of which £140.7m was recurring (+5%). This gave rise to pretax profit £0.3m ahead at £38m, for eps of 47.3p. After settling the NHS service failing fine at £11.2m (£1.7m less than feared), its net cash pile was left at £15.2m.EMIS has the no.1 or no.2 positions in its chosen markets and it has seen market share growth across the board - GP  systems (now stands at 57% share), community (20% share), pharmacy (37%), hospital pharmacy (36%) and A&E (22%). It might seem that EMIS has captured the lower hanging fruit but growth this year will benefit from reduced investment relatin ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe